The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · Oct 2024
Initial Cannulation Strategy Impacts Perioperative Outcomes of Acute Type A Dissection in High Volume Centers.
We performed an intention to treat analysis of initial cannulation strategy to assess impact on perioperative outcomes in acute type A dissection using multicenter data. ⋯ In high volume aortic centers, an initial cannulation strategy using Axillary access is associated with reduced risk of stroke compared to Femoral. Axillary cannulation should be the preferred strategy in experienced centers if anatomy and stability allow.
-
J. Thorac. Cardiovasc. Surg. · Oct 2024
Early clinical outcomes in men and women undergoing proximal thoracic aortic surgery - A Swedish population-based cohort study.
To investigate the association between female sex and 30-day mortality and postoperative complications in patients undergoing scheduled proximal thoracic aortic surgery in Sweden. ⋯ Women who underwent proximal thoracic aortic surgery had a two-fold higher unadjusted 30-day mortality risk, but the mortality risk was not significantly higher when age and comorbidities was taken into consideration.
-
J. Thorac. Cardiovasc. Surg. · Oct 2024
Initial Patient Characteristics of TSOG 102: A Multicenter Prospective Registry of Active Surveillance in Patients with Multiple Ground Glass Opacities.
Presentation with multiple ground glass opacities (GGOs) is an increasingly common occurrence, and the optimal management of these lesions is unclear. Active surveillance has been increasingly adopted as a management strategy for other low-grade malignancies. We hypothesized that active surveillance could be a feasible and safe option for patients with multiple GGOs. ⋯ Active surveillance, rather than immediate intervention, was an acceptable option to patients, and accrual to this registry trial was feasible. Safety endpoints and long-term outcomes will be assessed in the planned 5-year follow-up in accordance with the protocol.
-
J. Thorac. Cardiovasc. Surg. · Oct 2024
Soluble Mesothelin-Related Peptide as a Prognosticator in Pleural Mesothelioma Patients Receiving Checkpoint Immunotherapy.
Immune checkpoint therapy (ICT) has significantly impacted malignant pleural mesothelioma (MPM) treatment. Despite some promising results from combination therapies, nearly half of MPM patients do not benefit, underscoring the urgent need for reliable predictive biomarkers. This study assesses the prognostic value of serum soluble mesothelin-related peptide (SMRP) and PD-L1 levels in MPM patients receiving ICT. ⋯ SMRP is a promising serum biomarker for predicting survival in MPM patients treated with ICT and warrants prospective investigation.